| CTRI Number |
CTRI/2025/04/083778 [Registered on: 01/04/2025] Trial Registered Prospectively |
| Last Modified On: |
04/03/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group Trial |
|
Public Title of Study
|
Moringa oleifera leaf extract oral gel vs retino-a
cream in treatment of homogenous oral leukoplakia. |
|
Scientific Title of Study
|
Evaluating the therapeutic efficacy of Moringa oleifera leaf extract oral gel versus Retino-A cream in oral homogenous leukoplakia. A double blinded randomized controlled trial. |
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Pierce psalm.Yamarthi |
| Designation |
Mds |
| Affiliation |
Sibar institute of dental sciences |
| Address |
Room no1 Oral medicine and radiology, Sibar institute of dental sciences, Guntur, Andhra pradesh, India 522509.
Guntur ANDHRA PRADESH 522509 India |
| Phone |
7661994003 |
| Fax |
|
| Email |
piercepsalm@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
DR N PURNA CHANDRA RAO NAIK |
| Designation |
Proffessor |
| Affiliation |
Sibar institute of dental sciences |
| Address |
Room no 1 Oral medicine &Radiology Sibar
Institute of Dental Sciences Guntur
Guntur ANDHRA PRADESH 522509 India |
| Phone |
9989857600 |
| Fax |
|
| Email |
drpurnaoralmed@sids.ac.in |
|
Details of Contact Person Public Query
|
| Name |
Dr.N.Purna chandra rao naik |
| Designation |
Proffessor |
| Affiliation |
Sibar institute of dental sciences |
| Address |
Room no1 Oral medicine and radiology, Sibar institute of dental sciences, Guntur, Andhra pradesh, India 522509.
Guntur ANDHRA PRADESH 522509 India |
| Phone |
9989857600 |
| Fax |
|
| Email |
drpurnaoralmed@sids.ac.in |
|
|
Source of Monetary or Material Support
|
| Oral medicine and radiology, Sibar institute of dental sciences, Guntur, Andhra pradesh, India 522509. |
|
|
Primary Sponsor
|
| Name |
Pierce psalm Yamartthi |
| Address |
Room no1 Oral medicine and radiology, Sibar institute of dental sciences, Guntur, Andhra pradesh, India 522509. |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Pierce psalm Yamarthi |
Sibar institute of dental sciences |
Room no1 Oral medicine and radiology, Sibar institute of dental sciences, Guntur, Andhra pradesh, India 522509 Guntur ANDHRA PRADESH |
7661994003
piercepsalm@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Sibar institute of dental sciences |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: K132||Leukoplakia and other disturbancesof oral epithelium, including tongue, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Moringa oleifera leaf extract oral gel |
Evaluating therapeutic efficacy of Moringa oleifera
leaf extract oral gel for Homogenous Oral
Leukoplakia and will be reviewed periodically at an
interval of every 2 weeks for period of 2 months. |
| Comparator Agent |
Retino-A cream |
Evaluating therapeutic efficacy of Retino-A cream
for Homogenous Oral Leukoplakia and will be
reviewed periodically at an interval of every 2
weeks for period of 2 months. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
90.00 Year(s) |
| Gender |
Both |
| Details |
1.Subjects willing to participate in the study.
2.Subjects diagnosed with homogenous leukoplakia clinically. |
|
| ExclusionCriteria |
| Details |
• Non homogenous Leukoplakia.
• Pregnant and lactating women. |
|
|
Method of Generating Random Sequence
|
Coin toss, Lottery, toss of dice, shuffling cards etc |
|
Method of Concealment
|
Case Record Numbers |
|
Blinding/Masking
|
Participant and Investigator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Reduction in size of Homogenous Oral Leukoplakia lesion |
Baseline, 2nd week, 4th week, 6th week and 8th week |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
No secondary outcome measured. Any adverse
events will be noted |
Baseline, 2nd week, 4th week, 6th week and 8th
week |
|
|
Target Sample Size
|
Total Sample Size="40" Sample Size from India="40"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 2 |
|
Date of First Enrollment (India)
|
01/04/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Aim of study Evaluating the therapeutic efficacy of Moringa oleifera leaf extract oral gel 2 percentage versus Retino A cream 0.1 percentage in the management of homogenous oral leukoplakia.
Objectives of study 1.To evaluate the therapeutic efficacy of Moringa oleifera leaf extract oral gel 2 percentage in reducing the size of lesions in patients with homogeneous oral leukoplakia. 2.To assess the therapeutic efficacy of Retino A cream 0.1 percentage in reducing the size of lesions in patients with homogeneous oral leukoplakia. 3.To compare the efficacy of Moringa Oleifera leaf extract oral gel 2 percentage and Retino A cream 0.1 percentage in reducing lesion size in patients with homogenous oral leukoplakia.
Preparation of Moringa oleifera leaf extract Moringa oleifera leaves are harvested from the Moringa oleifera tree.Then the collected leaves should be washed with distilled water and shade dried for 4 to 5 days. Then the dried leaves are coarsely powdered in the grinder. Extraction of leaves will be done by maceration procedure using a hydroalcoholic method using 70 to 30 ethanol to distilled water. The leaves are to be transferred into a flask dipped in 70 percentage aqueous ethanolic solution for 72 hours in a shaker at 75 rpm and room temperature and ought to extraction repeatedly. Whatmans filter paper no.42 should be used to filter the solution. The obtained filtrate is then transferred to a crucible and dried over a water bath at 40 degreeC. The dry content obtained has to be weighed on the weighing machine. The extract obtained should be stored at 2 to 8 degreeC temperature.
Preparation of Moringa oleifera leaf extract gel The prepared leaf extract is subsequently treated with Carbopol 940 as a gelling agent. 2 percentage of the gel is prepared by adding 2gm of extract per 100 ml of distilled water. Later TEA Triethanolamine is added to enhance the gelling property. Methyl and ethyl paraben are to be added which are used as preservatives. The obtained gel will be stored in a sterile condition below 8 degreeC of temperature.
Methodology Each subject in group A will be given freshly prepared Moringa oleifera leaf extract oral gel 2 percentage and subjects in group B will be given commercially available Retino A cream 0.1 percentage. All the subjects will be instructed to apply topically over the lesion area 3 times a day and they will be asked to refrain from eating drinking and rinsing for at least 30 minutes after the application. They will also be informed about the possible allergic reactions and instructed to terminate the use of the drug in the event of any adverse reaction and to report immediately. All the subjects will be reviewed periodically at an interval of every 2 weeks for period of 2 months for the reduction in size of the lesion. All the collected data will be subjected to statistical analysis.
Statistical analysis 1.Descriptive statistics To calculate the means and standard deviation of all the parameters or variables in each group. 2.Paired t test for intra group comparison. 3.Independent t test for inter group comparison. |